上海宣泰医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 8 日 召开第二届董事会审计委员会第十五次会议、第二届董事会第十七次会议审议 通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在不影响 募集资金项目（以下简称"募投项目"）的建设和使用安排并有效控制风险的前 提下，合理使用额度不超过人民币 8,000 万元的部分闲置募集资金进行现金管 理。使用期限为自公司董事会审议通过之日起 12 个月内。在前述额度和期限范 围内，资金可以循环滚动使用。 公司董事会授权公司董事长在上述授权额度范围及期限内行使投资决策权 并签署相关合同等法律文件，具体事项由公司财务部负责实施。保荐机构国泰 海通证券股份有限公司（以下简称"保荐机构"）对本事项出具了明确同意的核 查意见。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公 开发行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资 金总额为人民币 42,483.58 万元，扣除与发行相关 ...

天眼查商业履历信息显示，上海宣泰医药科技股份有限公司，成立于2012年，位于上海市，是一家以从 事研究和试验发展为主的企业。企业注册资本45334万人民币，实缴资本45334万人民币。公司法定代表 人为郭明洁。 资金流向方面，今日主力资金净流出1307.87万元，占比成交额7.27%。其中，超大单净流出1017.85万 元、占成交额5.66%，大单净流出290.02万元、占成交额1.61%，中单净流出流入414.06万元、占成交额 2.3%，小单净流入893.81万元、占成交额4.97%。 通过天眼查大数据分析，上海宣泰医药科技股份有限公司共对外投资了5家企业，参与招投标项目153 次，知识产权方面有商标信息101条，专利信息56条，此外企业还拥有行政许可36个。 来源：金融界 宣泰医药最新一期业绩显示，截至2025一季报，公司营业总收入1.09亿元、同比减少2.23%，归属净利 润2048.93万元，同比减少10.51%，扣非净利润1906.76万元，同比减少12.33%，流动比率9.733、速动比 率8.720、资产负债率11.93%。 金融界消息 截至2025年7月30日收盘，宣泰医药（688247）报 ...

Group 1 - Datang Power achieved a total on-grid electricity of approximately 123.99 billion kWh for the first half of 2025, a year-on-year increase of 1.30%, with wind and solar power generation increasing by 31.27% and 36.35% respectively [1] - North Self Technology signed an equipment procurement contract with a total amount of 164 million yuan [1] - Jinchuan Co. reported a net profit of 1.38 billion yuan for the first half of 2025, a year-on-year decrease of 8.45%, with operating revenue of 6.96 billion yuan, an increase of 5.55% [1][2] Group 2 - Microchip Biotech expects a revenue of 407 million yuan for the first half of 2025, a year-on-year increase of 35%, and a net profit of approximately 30.06 million yuan, a year-on-year increase of 173% [3] - Zongheng Co. anticipates a revenue of 135 million yuan for the first half of 2025, a year-on-year increase of 61.72%, with a net loss of 34.68 million yuan, reducing losses by 18.34 million yuan compared to the previous year [5] - Tuojing Technology expects a revenue of 1.21 billion to 1.26 billion yuan for the second quarter of 2025, a year-on-year increase of 52% to 58%, with a net profit of 238 million to 247 million yuan, a year-on-year increase of 101% to 108% [7] Group 3 - Star Power reported a net profit of 73.42 million yuan for the first half of 2025, a year-on-year decrease of 13.44%, with total revenue of 1.52 billion yuan, an increase of 13.70% [8] - Xiamen Tungsten reported a net profit of 972 million yuan for the first half of 2025, a year-on-year decrease of 4.41%, with operating revenue of 19.18 billion yuan, an increase of 11.75% [9] - Yikang Pharmaceutical's subsidiary received approval for clinical trials of YKYY029 injection for hypertension [11] Group 4 - Mould Technology received a project designation for luxury car exterior parts, with an expected total sales of 2.044 billion yuan over a five-year lifecycle [13] - Jinzhik Technology won multiple projects from the State Grid and Southern Power Grid, with a total bid amount of 133 million yuan [14] - Changjiang Media plans to use up to 700 million yuan of idle funds to purchase financial products [16] Group 5 - Ningbo Gaofa plans to invest up to 20 million USD to establish a production base in Morocco [20] - Xuantai Pharmaceutical's subsidiary received EU GMP certification for solid dosage production lines [22] - Changhua Group received a project designation for key metal structural components from a domestic new energy vehicle company, with an expected total sales of 235 million yuan over a four-year lifecycle [23]

证券代码：688247 证券简称：宣泰医药 公告编号：2025-029 上海宣泰医药科技股份有限公司 自愿披露关于全资子公司通过欧盟 GMP 认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 7 月 18 日 一、GMP 证书相关情况 二、对公司的影响及风险提示 宣泰药业本次通过欧盟 EMA 的 GMP 认证，是继其通过 NMPA（中国国家 药品监督管理局）、FDA（美国食品药品监督管理局）、PMDA（日本独立行政 法人医药品医疗器械综合机构）、SFDA（沙特阿拉伯食品药品监督管理局）等 药政当局 GMP 认证后又一次良好的认证记录，意味着公司质量体系始终保持与 企业名称：江苏宣泰药业有限公司 生产地址：南通市海门区滨江街道珠海路 163 号 证书编号：NNGYK/29521-4/2025 认证产线：固体片剂车间 签发机关：匈牙利国家公共卫生和药房中心 国际标准接轨。这将有力促进公司产品海外市场的拓展，提高公司的市场竞争力； 同时持续支持公司向全球制药企业、生物技术企业提供一站式制剂研发生产服务， ...

Core Viewpoint - Xuantai Pharmaceutical's wholly-owned subsidiary, Jiangsu Xuantai Pharmaceutical Co., Ltd., has received the EU GMP certification, enhancing its international quality standards and market competitiveness [1] Group 1: Certification Achievements - The company has obtained the GMP certificate from the Hungarian National Public Health and Pharmacy Center for its solid tablet production line [1] - This certification follows previous GMP certifications from NMPA, FDA, PMDA, and SFDA, indicating a consistent alignment with international standards [1] Group 2: Market Implications - The EU GMP certification is expected to facilitate the company's expansion into overseas markets and improve its market competitiveness [1] - However, the production and sales of pharmaceuticals may be influenced by various factors such as market environment and channel expansion, leading to uncertainties in short-term operational performance [1]

Policy Developments - The National Healthcare Security Administration reported that the basic medical insurance coverage rate in China remains stable at over 95%, with 1.32662 billion people insured by the end of 2024 [2] - The total income of the national basic medical insurance fund for 2024 is projected to be CNY 34,913.37 billion, while total expenditures are expected to be CNY 29,764.03 billion, resulting in a current balance of CNY 4,639.17 billion [2] - Since the establishment of the National Healthcare Security Administration in 2018, 835 new drugs have been added to the medical insurance drug list, with over 5,400 million CNY in sales from newly negotiated drugs between 2018 and 2024 [2] Drug and Device Approvals - Bayer's non-hormonal drug elinzanetant has been approved by the UK Medicines and Healthcare products Regulatory Agency for treating moderate to severe vasomotor symptoms related to menopause [5] - Innovent Biologics' new BCL2 inhibitor mesutoclax has received FDA approval to commence clinical trials for treating myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndromes [6] - Tianyu Co., Ltd.'s subsidiary has passed the review for ezetimibe raw materials by the National Medical Products Administration, pending GMP compliance inspection results for market launch [7] Capital Market Activities - Innostellar Biotherapeutics has signed a ten-year exclusive promotion agreement with Golden Age Health for the commercialization of its gene therapy candidate LX101 in mainland China [9] Earnings Disclosures - Da'an Gene anticipates a net loss of CNY 140 million to 200 million for the first half of 2025 [11] - Huahai Pharmaceutical expects a net profit decline of 40% to 50% year-on-year, projecting a profit range of CNY 374 million to 449 million [12] - KingMed Diagnostics forecasts a net loss of CNY 95 million to 65 million for the first half of 2025, representing a significant year-on-year decline [13] - Xinmai Medical projects a net profit of CNY 304 million to 361 million for the first half of 2025, a decrease of 10.52% to 24.78% compared to the previous year [14] - Wantai Biological Pharmacy anticipates a net loss of CNY 130 million to 160 million for the first half of 2025 due to market pressures and policy adjustments [15] Industry Events - *ST Suwu has received a notice of administrative penalty from the China Securities Regulatory Commission for falsifying financial reports, which may lead to forced delisting [17] - This incident serves as a warning for the pharmaceutical industry to focus on genuine innovation and establish effective internal controls to mitigate risks associated with management [17] Shareholder Movements - Qihe Venture, a shareholder holding over 5% of Xuantai Pharmaceutical, plans to reduce its stake by up to 7 million shares, representing no more than 1.5441% of the company's total shares [19]

Group 1 - The core viewpoint of the news is that companies are actively engaging in share buyback and employee stock ownership plans to enhance investor confidence and align management interests with shareholders [1][2]. - Shenzhen Overseas Chinese Town Holdings Company plans to increase its stake in Huaqiang City A by investing between 111 million and 220 million RMB within six months, currently holding 48.78% of the total shares [1]. - Chengyi Pharmaceutical announced an employee stock ownership plan for 2025, targeting to raise up to 48.2864 million RMB, with a share price set at 5.02 RMB per share, covering up to 228 employees [1][2]. Group 2 - The employee stock ownership plan has performance targets for revenue and net profit from 2025 to 2027, with growth rates set at 30%, 55%, and 85% for revenue, and 35%, 65%, and 100% for net profit [2]. - Several companies have announced plans for share reductions by executives and major shareholders, including Jinzheng Co., which plans to reduce up to 28.8 million shares, equivalent to approximately 568 million RMB [3][4][5]. - The reduction plans are set to commence from July 15, indicating a trend of liquidity events in the market as companies adjust their shareholder structures [7][8].

Core Viewpoint - The major shareholder of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. plans to reduce its shareholding due to operational needs, with a maximum reduction of 7,000,000 shares, accounting for no more than 1.5441% of the total share capital [1][2]. Group 1: Major Shareholder Information - The major shareholder, Nanjing Qihe Venture Capital Partnership (Limited Partnership), holds 25,798,000 shares, representing 5.6907% of the total share capital [1][2]. - The shares held by the major shareholder were acquired prior to the company's initial public offering (IPO) and were released from restrictions on August 25, 2023 [1][2]. Group 2: Reduction Plan Details - The reduction plan involves a maximum of 7,000,000 shares, with a breakdown of up to 4,500,000 shares through centralized bidding and up to 2,500,000 shares through block trading [2]. - The reduction period for centralized bidding is set for three months starting 15 trading days after the announcement date, while the block trading will follow the same timeline [1][2]. Group 3: Compliance and Commitments - The major shareholder has previously committed to not transferring or managing the shares held prior to the IPO for 36 months and has set limits on the amount of shares that can be sold within specific time frames [4][5]. - The company confirms that the current reduction plan aligns with previously disclosed commitments and does not violate any regulations [5].

证券代码：688247 证券简称：宣泰医药 公告编号：2025-028 上海宣泰医药科技股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： | 股东名称 | 南京市栖和创业投资合伙企业（有限合伙） | | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 □是 √否 | 一、减持主体的基本情况 1 二、减持计划的主要内容 | 股东名称 | 南京市栖和创业投资合伙企业（有限合伙） | | --- | --- | | 计划减持数量 | 不超过：7,000,000 股 | | 计划减持比例 | 不超过：1.5441% | | 减持方式及对应减持数 | 集中竞价减持，不超过：4,500,000 股 | | 量 | 大宗交易减持，不超过：2,500,000 股 | | 减持期间 | 2025 年 8 月 5 日～2025 年 11 月 4 日 | | 拟减持股份来源 | IPO 前取得股份 | | 拟减持原因 | 股东自身经营需要 | 大 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-027 上海宣泰医药科技股份有限公司 自愿披露关于公司产品恩杂鲁胺片 获得美国 FDA 批准文号的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海宣泰医药科技股份有限公司（以下简称"公司"）收到美国食品 药品监督管理局（以下简称"美国 FDA"）的通知，公司向美国 FDA 申报的恩 杂鲁胺片的简略新药申请（以下简称"ANDA"，即美国仿制药申请）获得暂时 批准（Tentative Approval），现将相关情况公告如下： 一、药品基本情况 1、药品名称：恩杂鲁胺片 2、ANDA 号：219675 3、剂型：片剂 4、规格：40mg，80mg 5、申请事项：ANDA 二、药品的其他相关情况 恩杂鲁胺片是一种雄激素受体抑制剂，本次获批的适应症为：1）去势抵抗 性前列腺癌；2）转移性去势敏感性前列腺癌。此外，该产品已于 2024 年 8 月在 中国提交注册申请。 恩杂鲁胺（Enzalutamide），又称恩扎卢胺，是第二代雄激素受体（AR）抑 制剂 ...